Abstract
Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without ad......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
